Abeona Therapeutics (ABEO) Free Cash Flow (2011 - 2026)

Abeona Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$20.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 12.94% year-over-year to -$20.7 million in Q1 2026; TTM through Mar 2026 was -$79.4 million, a 34.7% decrease from a year earlier, with the FY2025 full-year figure at -$77.0 million, down 37.93% from the prior year.
• Free Cash Flow slipped to -$20.7 million in Q1 2026 per ABEO's latest filing, from -$11.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$5.8 million in Q3 2023 and bottomed at -$26.6 million in Q3 2025.
• The 5-year median for Free Cash Flow is -$13.4 million (2024), against an average of -$13.8 million.
• Across the five-year window, Free Cash Flow jumped 52.81% in 2022 and tumbled 118.76% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$14.3 million in 2022, then soared by 34.32% to -$9.4 million in 2023, then tumbled by 55.11% to -$14.5 million in 2024, then grew by 18.72% to -$11.8 million in 2025, then sank by 75.52% to -$20.7 million in 2026.
• Per Business Quant, the three latest ABEO Free Cash Flow figures stand at -$20.7 million (Q1 2026), -$11.8 million (Q4 2025), and -$26.6 million (Q3 2025).